PF-06305591
- Generic Name
- PF-06305591
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N4O
- CAS Number
- 1449473-97-5
- Unique Ingredient Identifier
- G5Y3F1X9MU
- Background
Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).
- Associated Conditions
- -
- Associated Therapies
- -
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 36
- Registration Number
- NCT05935280
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Cold Pressor Test is Used in This Study to Assess the Effect of PF-06305591 on Pain Intensity Evoked by Cold in Healthy Male Subjects
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01812265
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01797796
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Safety and Tolerability Study of Multiple Doses of PF-06305591
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT01776619
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01747941
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath